Active, not recruitingPHASE1, PHASE2NCT04542824

Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Genmab
Intervention: Epcoritamab (monotherapy)(biological)
Enrollment: 78 enrolled
Eligibility: 20 years · All sexes
Timeline: 2020 – 2027

Study locations (15)

Tohoku University Hoaspital, Sendai, Miyagi, Japan
Aichi Cancer Center Hospital, Aichi, Japan
NHO Nagoya Medical Center, Aichi, Japan
National Cancer Center Hospital East, Chiba, Japan
Matsuyama Red Cross Hospital, Ehime, Japan
National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
Fukushima Medical University Hospital, Fukushima, Japan
Kagoshima University Hospital, Kagoshima, Japan
Kyoto University Hospital, Kyoto, Japan
Kindai University Hospital, Osaka, Japan
Osaka University Hospital, Osaka, Japan
Cancer Institute Hospital of JFCR, Tokyo, Japan
National Cancer Center Hospital, Tokyo, Japan
Tokyo Medical University Hospital, Tokyo, Japan
Yamagata University Hospital, Yamagata, Japan

Collaborators

AbbVie

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04542824 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials